{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:15:11Z","timestamp":1792440911623,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007557","name":"California Institute of Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cell.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T10:41:35Z","timestamp":1740048095000},"page":"901-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Advances in the study and treatment of genetic cardiomyopathies"],"prefix":"10.1016","volume":"188","author":[{"given":"Victoria N.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene M.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-7924","authenticated-orcid":false,"given":"Carolyn Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2025.01.011_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jchf.2023.05.002","article-title":"Nonresponse to Heart Failure Therapy: An Important Trajectory","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/gim.2016.90","article-title":"Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples","volume":"19","author":"Walsh","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.975076","article-title":"Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies","volume":"13","author":"Kawana","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cell.2025.01.011_bib4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.jacc.2023.08.041","article-title":"Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives","volume":"82","author":"Nielsen","year":"2023","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib5","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","article-title":"Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy","volume":"42","author":"Marston","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib7","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.ajhg.2023.08.003","article-title":"The penetrance of rare variants in cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings","volume":"110","author":"McGurk","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","article-title":"Evidence-Based Assessment of Genes in Dilated Cardiomyopathy","volume":"144","author":"Jordan","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.119.037661","article-title":"Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy","volume":"141","author":"Mazzarotto","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib10","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of Hypertrophic Cardiomyopathy: A report of the American heart association\/American college of cardiology joint committee on clinical practice guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib11","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.jcmg.2021.03.032","article-title":"Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care","volume":"14","author":"Captur","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.cell.2025.01.011_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41576-020-0255-7","article-title":"Exploring human genomic diversity with gnomAD","volume":"21","author":"Koch","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.cell.2025.01.011_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/CIRCGEN.119.002823","article-title":"Genetic Studies of Hypertrophic Cardiomyopathy in Singaporeans Identify Variants in TNNI3 and TNNT2 That Are Common in Chinese Patients","volume":"13","author":"Pua","year":"2020","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib13","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1093\/eurheartj\/ehad372","article-title":"Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy","volume":"44","author":"Allouba","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.122.062517","article-title":"Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry","volume":"148","author":"Abou Alaiwi","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005191","article-title":"Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy","volume":"11","author":"Lee","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib20","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009521","article-title":"Defects in the proteome and metabolome in human hypertrophic cardiomyopathy","volume":"15","author":"Previs","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCGENETICS.113.000448","article-title":"Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy","volume":"7","author":"Helms","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib26","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","article-title":"Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy","volume":"134","author":"Helms","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib27","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.118.037264","article-title":"Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy","volume":"139","author":"Maurizi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers","volume":"76","author":"Lorenzini","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib31","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/CIRCIMAGING.112.000333","article-title":"T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy","volume":"6","author":"Ho","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.cell.2025.01.011_bib34","article-title":"Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers","volume":"10","author":"Hughes","year":"2021","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.cell.2025.01.011_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.110.985812","article-title":"Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy","volume":"124","author":"Maron","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/ehjci\/jey095","article-title":"Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers","volume":"19","author":"Groarke","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.cell.2025.01.011_bib37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/CIRCIMAGING.114.002411","article-title":"Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy","volume":"7","author":"Captur","year":"2014","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.cell.2025.01.011_bib38","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2011.07.019","article-title":"Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy","volume":"108","author":"Lakdawala","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib39","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1172\/JCI42028","article-title":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-\u03b2","volume":"120","author":"Teekakirikul","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib41","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","article-title":"Targeting the sarcomere in inherited cardiomyopathies","volume":"19","author":"Lehman","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2025.01.011_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cardfail.2022.10.022","article-title":"Efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: Interim results from the randomized evaluation of dosing with ck-3773274 in hypertrophic cardiomyopathy open label extension study","volume":"29","author":"Masri","year":"2023","journal-title":"J.\u00a0Card. Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib46","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for Septal Reduction Therapy: Outcomes through 32\u00a0weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.01.011_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/circ.148.suppl_1.15822","article-title":"Abstract 15822: Cardiac Effects of EDG-7500, a Novel Cardiac Sarcomere Regulator: In\u00a0vitro and in\u00a0vivo Evidence for Slowing Isovolumic Contraction and Improved Ventricular Compliance","volume":"148","author":"Del Rio","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib51","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cvr\/cvae004","article-title":"Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors","volume":"120","author":"Wijnker","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.2864","article-title":"Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure","volume":"25","author":"Talha","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib54","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.108.840827","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria","volume":"121","author":"Marcus","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib55","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.jacc.2008.09.019","article-title":"Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity","volume":"52","author":"Sen-Chowdhry","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib56","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.hrthm.2019.09.019","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cell.2025.01.011_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131447","article-title":"Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report","volume":"395","author":"Corrado","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib58","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.hrthm.2022.05.038","article-title":"Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy","volume":"19","author":"de Brouwer","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cell.2025.01.011_bib59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41436-018-0039-z","article-title":"Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Hershberger","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib60","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacep.2017.12.003","article-title":"Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell-cell adhesion structures","volume":"4","author":"Begay","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"10.1016\/j.cell.2025.01.011_bib61","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.121.053521","article-title":"Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants","volume":"144","author":"Gigli","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib62","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2016.08.058","article-title":"Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A\/C Mutation Carriers","volume":"68","author":"Kumar","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jacc.2022.04.035","article-title":"LMNA Variants and Risk of Adult-Onset Cardiac Disease","volume":"80","author":"Lazarte","year":"2022","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib64","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","article-title":"Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"141","author":"Smith","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003081","article-title":"Cardiocutaneous Features of Autosomal Dominant Desmoplakin-Associated Arrhythmogenic Cardiomyopathy","volume":"13","author":"Hylind","year":"2020","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12471-018-1211-4","article-title":"Prevalence and cardiac phenotype of patients with a phospholamban mutation","volume":"27","author":"Hof","year":"2019","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib67","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","article-title":"Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction","volume":"42","author":"Verstraelen","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib68","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005371","article-title":"Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy","volume":"12","author":"Parikh","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib69","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/CIRCULATIONAHA.117.031947","article-title":"RBM20 Mutations Induce an Arrhythmogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling","volume":"138","author":"van den Hoogenhof","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib70","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/eurheartj\/ehx808","article-title":"Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias","volume":"39","author":"Verdonschot","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009352","article-title":"Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant","volume":"15","author":"Henkens","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib72","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/S0735-1097(17)35952-1","article-title":"Integrated analysis of the clinical manifestations and phenotypic drivers of titin cardiomyopathy","volume":"69","author":"Tayal","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6520","article-title":"Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators","volume":"2","author":"Corden","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cell.2025.01.011_bib74","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2017.08.063","article-title":"Phenotype and Clinical Outcomes of Titin Cardiomyopathy","volume":"70","author":"Tayal","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib75","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","article-title":"Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations","volume":"72","author":"Dom\u00ednguez","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib76","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCGENETICS.114.001003","article-title":"Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia\/Cardiomyopathy Patients and Family Members","volume":"8","author":"Groeneweg","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib77","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.stem.2020.12.016","article-title":"Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes","volume":"28","author":"Shah","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.cell.2025.01.011_bib78","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/cvr\/cvaa300","article-title":"Haploinsufficiency of Tmem43 in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy","volume":"117","author":"Rouhi","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib79","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurheartj\/ehu077","article-title":"The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus","volume":"36","author":"Milting","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCRESAHA.123.322750","article-title":"Interaction of Filamin C With Actin Is Essential for Cardiac Development and Function","volume":"133","author":"Zhou","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib81","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/CIRCRESAHA.120.317076","article-title":"Filamin C Cardiomyopathy Variants Cause Protein and Lysosome Accumulation","volume":"129","author":"Agarwal","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib82","first-page":"2776","article-title":"Filamin C is a highly dynamic protein associated with fast repair of myofibrillar microdamage","volume":"25","author":"Leber","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib83","doi-asserted-by":"crossref","first-page":"H1220","DOI":"10.1152\/ajpheart.00601.2011","article-title":"Desmin-related cardiomyopathy: an unfolding story","volume":"301","author":"McLendon","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cell.2025.01.011_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/hmg\/ddl453","article-title":"Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A\/C and emerin in cardiomyocytes","volume":"16","author":"Heydemann","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib85","series-title":"Dystrophin: Gene, Protein and Cell Biology","author":"Brown","year":"1997"},{"key":"10.1016\/j.cell.2025.01.011_bib86","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.ajpath.2017.07.017","article-title":"Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy","volume":"187","author":"Quattrocelli","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cell.2025.01.011_bib87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.hrthm.2024.07.008","article-title":"Electrophysiologic and cardiovascular manifestations of Duchenne and Becker muscular dystrophies","volume":"22","author":"Hakimi","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cell.2025.01.011_bib88","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1093\/eurheartj\/ehad561","article-title":"Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure","volume":"44","author":"Cannie","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib89","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12551-021-00829-2","article-title":"Desmosomes: emerging pathways and non-canonical functions in cardiac arrhythmias and disease","volume":"13","author":"Zhang","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.cell.2025.01.011_bib90","article-title":"Clinical features and outcomes in carriers of pathogenic desmoplakin variants","volume":"46","author":"Gasperetti","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180254","article-title":"Susceptibility to innate immune activation in genetically mediated myocarditis","volume":"134","author":"Selgrade","year":"2024","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib92","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/jpm12101680","article-title":"Adipogenic Signaling Promotes Arrhythmia Substrates before Structural Abnormalities in TMEM43 ARVC","volume":"12","author":"Vasireddi","year":"2022","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib93","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1172\/JCI27751","article-title":"Suppression of canonical Wnt\/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy","volume":"116","author":"Garcia-Gras","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib94","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/eurheartj\/ehy567","article-title":"An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis","volume":"39","author":"Chatterjee","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib95","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1161\/CIRCULATIONAHA.121.057329","article-title":"Defective Desmosomal Adhesion Causes Arrhythmogenic Cardiomyopathy by Involving an Integrin-\u03b1V\u03b26\/TGF-\u03b2 Signaling Cascade","volume":"146","author":"Schinner","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib96","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/cvr\/cvac072","article-title":"Spatial transcriptomics unveils ZBTB11 as a regulator of cardiomyocyte degeneration in arrhythmogenic cardiomyopathy","volume":"119","author":"Boogerd","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib97","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1074\/jbc.RA118.001938","article-title":"Dilated cardiomyopathy myosin mutants have reduced force-generating capacity","volume":"293","author":"Ujfalusi","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cell.2025.01.011_bib98","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1242\/jeb.125930","article-title":"Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human \u03b2-cardiac myosin","volume":"219","author":"Spudich","year":"2016","journal-title":"J.\u00a0Exp. Biol."},{"key":"10.1016\/j.cell.2025.01.011_bib99","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1172\/JCI74523","article-title":"RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing","volume":"124","author":"Maatz","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.119.039573","article-title":"Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants","volume":"140","author":"Haggerty","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/auto.7.7.15844","article-title":"BAG3 and friends: co-chaperones in selective autophagy during aging and disease","volume":"7","author":"Behl","year":"2011","journal-title":"Autophagy"},{"key":"10.1016\/j.cell.2025.01.011_bib102","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1172\/JCI95839","article-title":"BAG3 plays a central role in proteostasis in the heart","volume":"127","author":"Mizushima","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib103","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2010.09.084","article-title":"SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism","volume":"57","author":"McNair","year":"2011","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib104","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/01.CIR.0000144458.58660.BB","article-title":"SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia","volume":"110","author":"McNair","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0735-1097(02)02954-6","article-title":"Natural history of dilated cardiomyopathy due to lamin A\/C gene mutations","volume":"41","author":"Taylor","year":"2003","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib106","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199912023412302","article-title":"Missense mutations in the rod domain of the lamin A\/C gene as causes of dilated cardiomyopathy and conduction-system disease","volume":"341","author":"Fatkin","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib107","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCULATIONAHA.120.052395","article-title":"Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy","volume":"143","author":"Goli","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1505517","article-title":"Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies","volume":"374","author":"Ware","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib109","doi-asserted-by":"crossref","first-page":"H1283","DOI":"10.1152\/ajpheart.00249.2012","article-title":"The ubiquitin proteasome system in human cardiomyopathies and heart failure","volume":"304","author":"Day","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cell.2025.01.011_bib110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.01.011_bib111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.yjmcc.2020.08.018","article-title":"Under construction: The dynamic assembly, maintenance, and degradation of the cardiac sarcomere","volume":"148","author":"Martin","year":"2020","journal-title":"J.\u00a0Mol. Cell. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib112","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cell.2025.01.011_bib113","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in\u00a0vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib114","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jmedgenet-2019-106394","article-title":"FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy","volume":"57","author":"Brun","year":"2020","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.cell.2025.01.011_bib115","first-page":"2968","article-title":"A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers","volume":"45","author":"Carrick","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib116","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","article-title":"Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies","volume":"140","author":"Wahbi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib118","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2018.03.462","article-title":"Genetic Etiology for Alcohol-Induced Cardiac Toxicity","volume":"71","author":"Ware","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib119","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cell.2025.01.011_bib120","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1001\/jama.2018.18179","article-title":"Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation","volume":"320","author":"Choi","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2025.01.011_bib121","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.jacc.2017.03.530","article-title":"Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy","volume":"69","author":"Tayal","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.cell.2025.01.011_bib122","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ejhf.2463","article-title":"The response to cardiac resynchronization therapy in LMNA cardiomyopathy","volume":"24","author":"Sidhu","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib123","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011548","article-title":"REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy","volume":"17","author":"Garcia-Pavia","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cell.2025.01.011_bib125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.118.036965","article-title":"Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation","volume":"140","author":"Zaleta-Rivera","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib126","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1152\/physiolgenomics.00021.2020","article-title":"Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes","volume":"52","author":"Dainis","year":"2020","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.cell.2025.01.011_bib127","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In\u00a0vivo somatic cell base editing and prime editing","volume":"29","author":"Newby","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2025.01.011_bib128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.cell.2025.01.011_bib129","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib130","article-title":"LAMP2 Cardiomyopathy: Consequences of Impaired Autophagy in the Heart","volume":"10","author":"Alcalai","year":"2021","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.cell.2025.01.011_bib131","doi-asserted-by":"crossref","DOI":"10.1161\/circ.146.suppl_1.11117","article-title":"Abstract 11117: Phase 1 Danon disease results: The first single dose intravenous (IV) gene therapy (RP-A501) with recombinant adeno-associated virus (AAV9:LAMP2B) for a monogenic cardiomyopathy","volume":"146","author":"Rossano","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib132","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.10727","article-title":"Abstract 10727: Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease","volume":"144","author":"Greenberg","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib133","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40265-023-01836-1","article-title":"Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression","volume":"83","author":"Ertl","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.cell.2025.01.011_bib134","article-title":"Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease","author":"Greenberg","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.01.011_bib136","article-title":"Gene Therapy Mediates Therapeutic Improvement in Cardiac Hypertrophy and Survival in a Murine Model of MYBPC3-Associated Cardiomyopathy","author":"Greer-Short","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2025.01.011_bib137","first-page":"256","article-title":"Reversal of cardiac hypertrophy with an optimized MYBPC3 gene therapy","volume":"29","author":"Lombardi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2025.01.011_bib138","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004305","article-title":"AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans","volume":"17","author":"van Opbergen","year":"2024","journal-title":"Circ. Genom. Precis. Med."},{"key":"10.1016\/j.cell.2025.01.011_bib139","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","article-title":"Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics","volume":"2","author":"Bradford","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.cell.2025.01.011_bib140","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","article-title":"Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy","volume":"2","author":"Kyriakopoulou","year":"2023","journal-title":"Nat CardioVasc Res"},{"key":"10.1016\/j.cell.2025.01.011_bib141","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1016\/j.ymthe.2022.07.003","article-title":"AAV capsid engineering identified two novel variants with improved in\u00a0vivo tropism for cardiomyocytes","volume":"30","author":"Rode","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cell.2025.01.011_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in\u00a0vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2025.01.011_bib143","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2025.01.011_bib144","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in\u00a0vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cell.2025.01.011_bib145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2025.01.011_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.3301","article-title":"Effective cardiac mRNA delivery using lipid nanoparticles","volume":"44","author":"Labonia","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cell.2025.01.011_bib147","first-page":"1253","article-title":"Gene therapies for sickle cell disease: Effectiveness and value","volume":"29","author":"Nikitin","year":"2023","journal-title":"J.\u00a0Manag. Care Spec. Pharm."},{"key":"10.1016\/j.cell.2025.01.011_bib148","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.186","article-title":"A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies","volume":"35","author":"Abuloha","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cell.2025.01.011_bib149","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart Disease and Stroke Statistics-2021\u00a0Update: A Report From the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cell.2025.01.011_bib150","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCULATIONAHA.119.040676","article-title":"Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy","volume":"140","author":"Chelko","year":"2019","journal-title":"Circulation"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867425000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:05:49Z","timestamp":1771556749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867425000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0092867425000406"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2025.01.011","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the study and treatment of genetic cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}